Welcome to our dedicated page for INTEG news (Ticker: integ), a resource for investors and traders seeking the latest updates and insights on INTEG stock.
Integrum (INTEG) is a Swedish medical innovator transforming amputee care through its OPRA™ Implant System. This page aggregates official updates about clinical trials, financial results, and strategic partnerships for investors and healthcare professionals.
Access timely reports on the company's US Department of Defense-funded transtibial amputation study at Walter Reed Medical Center, quarterly financial disclosures, and regulatory progress updates. Our curated news collection helps stakeholders track both technological advancements and business developments.
Key updates include implant system innovations, partnership announcements with medical institutions, and analysis of financial performance metrics. Bookmark this page for verified information directly from company filings and press releases, maintained for accuracy and relevance.
Integrum AB (Nasdaq First North: INTEG B) has announced a new compensation package for Board Director and Acting CEO Scott Flora, focusing on performance-based incentives during the company's strategic transition. The package includes 200,000 Stock Appreciation Rights (SARs) with a maximum compensation of SEK 60 per SAR and a base price of SEK 29.30.
The SARs will vest at a rate of 20% every three months starting June 1, 2025, and can be exercised between September 1-October 31, 2026. Unvested SARs will lapse without payment. The company maintains flexibility to pay in either stock or cash. As part of this restructuring, Flora's fixed compensation will be reduced. This adjustment aligns with the company's executive compensation guidelines approved at the latest shareholders' meeting.
Integrum AB (INTEG B) has announced compelling results from a two-year follow-up study conducted by Walter Reed National Military Medical Center on their OPRA™ Implant System for transfemoral amputees. The Level II Evidence study, focusing on the latest version introduced in 2017, demonstrates significant advantages over traditional socket prostheses.
The study revealed several key achievements:
- 100% implant survival rate
- Reduced infection and complication rates compared to previous data
- Increased prosthetic use
- Improved mobility and quality of life for patients
The research, published in Clinical Orthopaedics and Related Research (CORR), was conducted by a team led by Dr. Benjamin K. Potter and Dr. Jonathan Forsberg. The findings are expected to drive further adoption among US health providers and potentially increase insurance provider reimbursement coverage.
